Sixth Consecutive "Best CRO" Award Nomination For Accelovance
ROCKVILLE, Md., March 26, 2013 /PRNewswire-USNewswire/ -- Accelovance, Inc., a Maryland based contract research organization (CRO), was nominated for the 2013 ViE "Best CRO" Award for the sixth year in a row and is a confirmed finalist in this award category. Therapeutically focused on vaccines, infectious disease, immunology and oncology, Accelovance was a recipient of the award, as determined by an international panel of independent judges, previously in 2009, 2010 and 2011. The award complements a strong first quarter that announced strong leadership team additions and a successful CRO acquisition earlier this month.
"This nomination is a reflection of how we have served clients over the past 12-18 months with a diverse offering; flexible CRO services, research dedicated Vaccine Centers of Excellence and our Patient Recruitment solutions that include our Clinical Call Center," commented Stephen J. Trevisan, President and Chief Executive Officer. "It is an honor to be recognized again and again as one of the best in the industry, in this niche space."
The World Vaccine Congress – Washington and its annual Vaccine Industry Excellence (ViE) Awards reception will be held in late April at the Gaylord National Harbor facility in Maryland. The ViE awards were established to honor the excellence and accomplishments of vaccine and infectious disease service providers, Sponsors, Non Government Organizations (NGOs), clinical sites, manufacturers and strategic partnerships.
Since its inception in 2005, Accelovance has catered to the niche market of vaccines and infectious disease with cost-effective, integrated clinical solutions that accelerate study timelines and also reduce overall study costs. Fixed price budgets and performance guarantees have helped define the level of execution and control Accelovance brings to such studies. Over the past 12 months, Accelovance has supported government-funded Sponsors, top five vaccine manufacturers and biotech companies in Phase I-IV clinical studies; several First in Man and Phase III pivotal programs. These have included novel manufacturing methods, unique delivery methods, biodefense programs and traditional vaccines for pediatric, adolescent, adult and elderly populations.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV